Learn How to Make a Presentation to a Biotech Venture Capitalist.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c39202) has announced the addition of "Executive Reports: Successfully Pitching to Biotechnology Venture Capitalists (VCs) - The Over-Arching Issues You Need to Know" to their offering.

This 23-page research report written for biotech entrepreneurs outlines the fundamentals of securing venture capital. From how long your first presentation should be to what VCs want to know up front; from questions to ask and answer to addressing major issues, this report covers the ins and outs of pitching to biotech VCs, touching on the important and highlighting the essential.

Some areas explored include: who should come to the first meeting, execution risk, goals for the first meeting, key questions, what should be the heart of your pitch, and where you go from the first meeting.

This Executive Report is written by:

1. Charlotte P. Clark, Managing Director, POSCO BioVentures - "Key Points for your Pitch";

2. Jonathan J. Fleming, Managing General Partner, Oxford Bioscience Partners - "From the First Meeting to Receiving the Check";

3. A. Dana Callow Jr., Managing General Partner, Boston Millennia Partners - "Essential Preparation for Effective Presentation";

4. Christine D. Copple, Ph.D., President and CEO, Starise Ventures Inc. - "Presenting to a VC in Biotech: A Five Minute Overview";

5. T. Forcht Dagi, MD, MPH, MBA, FACS, FCCM, Managing Partner, Cordova Ventures - "Securing and Holding Investor Interest";

6. William Kieger, President, Aurora Capital Group - "Keys to a Successful Presentation".

About Executive Reports:

Executive Reports offer focused, hard-hitting advice from the leaders of some of Americas top companies, packaged in a concise, readable format. Each research report provides readers with 3 to 5 strategies that will have a direct financial impact on their business. While not meant as a comprehensive guide, each report includes quick-hit items that can immediately impact specific business strategies. Executive authors drill down to the central issues surrounding each topic area and dispense expert advice in concise, direct language. Executive Reports feature leading professionals selected by the Editorial Board based on their experience, research, and standing within the professional community.

Key Points for your Pitch:

Charlotte P. Clark, Managing Director, POSCO BioVentures

If I were coaching an entrepreneur on how to make a presentation to a biotech venture capitalist, I would advise the entrepreneur around these points:

--don't read your slides

--don't assume too much scientific background or too little

--be succinct and clear.

We want to know:

--what your technology is

--why it's better than what's already out there

--how protected it is - do you have a freedom to operate opinion?

--how strong your management team is

--how much money you are raising, how far it will take you and how long it will last

--who your current investors are, if any

--if you have a lead investor.

Keep your first presentation to less than thirty minutes. Questions will take up the rest of the hour. If you get more than an hour, you are very lucky.

A PowerPoint presentation to a venture capitalist is fine, but the presenter should never read the slides. Send the presentation ahead of time electronically - it makes for a more interesting and interactive session if we've had time to digest it and consider the questions it raises. But no handouts please, we hate paper.

Regarding who should come to the presentation, we have no real preference, but the CEO and the top scientist should be there. If others have a role - the clinical or regulatory person if you are in clinical trials could be helpful.

When presenting to a venture capitalist, an entrepreneur needs to be direct, honest, and enthusiastic - you are a salesperson (soft sell, NOT hard!).

For more information visit http://www.researchandmarkets.com/reports/c39202